PDF icon PDF herunterladen
Aktuelle Dermatologie 2003; 29(10): 409-414
DOI: 10.1055/s-2003-43491
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Neue monoklonale Antikörper und ihr Einsatz in der Dermatologie

New Monoclonal Antibodies and their Use in the Field of DermatologyK.  Steinbrink1 , J.  Knop1
  • 1Hautklinik der Universität Mainz
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
07. November 2003 (online)

Auch verfügbar aufeRef
  Lizenzen und Reprints
Preview

Zusammenfassung

Aufgrund weitreichender Erkenntnisse im Bereich der Immunologie und dem Fortschritt molekularbiologischer Methoden konnten in den letzten Jahren verschiedene neue Therapiestrategien unter Anwendung monoklonaler Antikörper oder Fusionsproteinen entwickelt werden. Mithilfe dieser neuen Behandlungsmethoden ist es möglich, sehr spezifisch auf molekularer Ebene unterschiedliche Krankheitsbilder zu beeinflussen. Im vorliegenden Übersichtsartikel werden die bekannten Daten zum therapeutischen Einsatz der neuen Immunmodulatoren im Bereich der Dermatologie zusammengefasst.

Abstract

Advances in immunological research and progress in molecular methods have led to the development of new therapeutic strategies compassing monoclonal antibodies and fusion proteins in the last years. These immunomodulators which are directed against key components of immunological processes have been designed in an attempt to produce safer and more selective immunosuppressive agents. This review summarizes much of the available literature describing the use of monoclonal antibodies and fusion proteins in the treatment of dermatological diseases.

Literatur

  • 1 Galadari H, Fuchs B, Lebwohl M. Newly available treatments for psoriatic arthritis and their impact on skin psoriasis.  Int J Dermatol. 2003;  42 231-237
    CrossrefPubMedSuche in Google Scholar
  • 2 Weinberg J M, Saini R. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.  Cutis. 2003;  71 25-29
    PubMedSuche in Google Scholar
  • 3 Chaudhari U, Romano P, Mulcahy L D, Dooley L T, Baker D G, Gottlieb A B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.  Lancet. 2001;  357 1842-1847
    CrossrefPubMedSuche in Google Scholar
  • 4 Schopf R E, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab.  J Am Acad Dermatol. 2002;  46 886-891
    CrossrefPubMedSuche in Google Scholar
  • 5 Gottlieb A B, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U, Dooley L T, Fasanmade A A, Wagner C L. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris.  J Am Acad Dermatol. 2003;  48 68-75
    CrossrefPubMedSuche in Google Scholar
  • 6 Kolde G, Muche J M, Schulze P, Fischer P, Lichey J. Infliximab: a promising new treatment option for ulcerated necrobiosis lipoidica.  Dermatology. 2003;  206 180-181
    CrossrefPubMedSuche in Google Scholar
  • 7 Serio R N. Infliximab treatment of sarcoidosis.  Ann Pharmacother. 2003;  37 577-581
    CrossrefPubMedSuche in Google Scholar
  • 8 Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross W L, Gause A. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis.  Rheumatology (Oxford). 2002;  41 1303-1307
    CrossrefPubMedSuche in Google Scholar
  • 9 Sfikakis P P. Behcžet's disease: a new target for anti-tumour necrosis factor treatment.  Ann Rheum Dis. 2002;  61 51-53
    PubMedSuche in Google Scholar
  • 10 Mease P J, Goffe B S, Metz J, VanderStoep A, Finck B, Burge D J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.  Lancet. 2000;  356 385-390
    CrossrefPubMedSuche in Google Scholar
  • 11 Iyer S, Yamauchi P, Lowe N J. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy.  Br J Dermatol. 2002;  146 118-121
    CrossrefPubMedSuche in Google Scholar
  • 12 Mease P J, Kivitz A, Burch F, Siegel E, Cohen S, Burge D. Improvement in disease activity inapteints with psoriatic arthritis receiving etanercept (Enbrel): Results of a phase III multicenter clinical trial.  Arthritis Rheum. 2001;  44 S90
    PubMedSuche in Google Scholar
  • 13 Gardam M A, Keystone E C, Menzies R, Manners S, Skamene E, Long R, Vinh D C. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.  Lancet Infect Dis. 2003;  3 148-155
    PubMedSuche in Google Scholar
  • 14 Gottlieb A B, Lebwohl M, Shirin S, Sherr A, Gilleaudeau P, Singer G, Solodkina G, Grossman R, Gisoldi E, Phillips S, Neisler H M, Krueger J G. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study.  J Am Acad Dermatol. 2000;  43 595-604
    CrossrefPubMedSuche in Google Scholar
  • 15 Krueger J G, Walters I B, Miyazawa M, Gilleaudeau P, Hakimi J, Light S, Sherr A, Gottlieb A B. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis.  J Am Acad Dermatol. 2000;  43 448-458
    CrossrefPubMedSuche in Google Scholar
  • 16 Martin A, Gutierrez E, Muglia J, McDonald C J, Guzzo C, Gottlieb A, Pappert A, Garland W T, Bagel J, Bacha P. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis.  J Am Acad Dermatol. 2001;  45 871-878
    CrossrefPubMedSuche in Google Scholar
  • 17 Abrams J R, Kelley S L, Hayes E, Kikuchi T, Brown M J, Kang S, Lebwohl M G, Guzzo C A, Jegasothy B V, Linsley P S, Krueger J G. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells.  J Exp Med. 2000;  192 681-694
    CrossrefPubMedSuche in Google Scholar
  • 18 Abrams J R, Lebwohl M G, Guzzo C A, Jegasothy B V, Goldfarb M T, Goffe B S, Menter A, Lowe N J, Krueger G, Brown M J, Weiner R S, Birkhofer M J, Warner G L, Berry K K, Linsley P S, Krueger J G, Ochs H D, Kelley S L, Kang S. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.  J Clin Invest. 1999;  103 1243-1252
    CrossrefPubMedSuche in Google Scholar
  • 19 Papp K, Bissonnette R, Krueger J G, Carey W, Gratton D, Gulliver W P, Lui H, Lynde C W, Magee A, Minier D, Ouellet J P, Patel P, Shapiro J, Shear N H, Kramer S, Walicke P, Bauer R, Dedrick R L, Kim S S, White M, Garovoy M R. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody.  J Am Acad Dermatol. 2001;  45 665-674
    CrossrefPubMedSuche in Google Scholar
  • 20 Gottlieb A B, Krueger J G, Wittkowski K, Dedrick R, Walicke P A, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.  Arch Dermatol. 2002;  138 591-600
    CrossrefPubMedSuche in Google Scholar
  • 21 Ellis C N, Krueger G G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.  N Engl J Med. 2001;  345 248-255
    CrossrefPubMedSuche in Google Scholar
  • 22 Krueger G G, Papp K A, Stough D B, Loven K H, Gulliver W P, Ellis C N. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.  J Am Acad Dermatol. 2002;  47 821-833
    CrossrefPubMedSuche in Google Scholar
  • 23 Lowe N J, Gonzalez J, Bagel J, Caro I, Ellis C N, Menter A. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy.  Int J Dermatol. 2003;  42 224-230
    CrossrefPubMedSuche in Google Scholar
  • 24 Ellis C N, Mordin M M, Adler E Y. Effects of Alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial.  Am J Clin Dermatol. 2003;  4 131-139
    PubMedSuche in Google Scholar
  • 25 Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rutuximab.  Ann Oncol. 2003;  14 520-535
    CrossrefPubMedSuche in Google Scholar
  • 26 Heinzerling L M, Urbanek M, Funk J O, Peker S, Bleck O, Neuber K, Burg G, von Den Driesch P, Dummer R. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.  Cancer. 2000;  89 1835-1844
    CrossrefPubMedSuche in Google Scholar
  • 27 Paul T, Radny P, Krober S M, Paul A, Blaheta H J, Garbe C. Intralesional rutuximab for cutaneous B-cell lymphoma.  Br J Dermatol. 2001;  144 1239-1243
    CrossrefPubMedSuche in Google Scholar
  • 28 Bonnekoh B, Schulz M, Franke I, Gollnick H. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rutuximab.  J Cancer Res Clin Oncol. 2002;  128 161-166
    CrossrefPubMedSuche in Google Scholar
  • 29 Garbea A, Dippel E, Hildenbrand R, Bleyl U, Schadendorf D, Goerdt S. Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer.  Br J Dermatol. 2002;  146 144-147
    CrossrefPubMedSuche in Google Scholar
  • 30 Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy.  Nature. 1988;  332 323-327
    CrossrefPubMedSuche in Google Scholar
  • 31 Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, Rosenblad E, Tjonnfjord G, Wiklund T, Osterborg A. Phase II study of alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) in patients with advanced mycosis fungoides/Sezary syndrome.  Blood. 2003;  101 4267-4272
    CrossrefPubMedSuche in Google Scholar
  • 32 Duvic M, Kuzel T M, Olsen E A, Martin A G, Foss F M, Kim Y H, Heald P W, Bacha P, Nichols J, Liepa A. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK(R)).  Clin Lymphoma. 2002;  2 222-2228
    PubMedSuche in Google Scholar
  • 33 Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J. Ivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.  J Clin Oncol. 2001;  19 376-388
    PubMedSuche in Google Scholar
  • 34 Salopek T G, Logsetty S, Tredget E E. Anti-CD20 chimeric monoclonal antibody (rutuximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder.  J Am Acad Dermatol. 2002;  47 785-788
    CrossrefPubMedSuche in Google Scholar
  • 35 Herrmann G, Hunzelmann N. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rutuximab).  Br J Dermatol. 2003;  148 602-603
    CrossrefPubMedSuche in Google Scholar
  • 36 Anolik J H, Campbell D, Felgar R E, Young F, Sanz I, Rosenblatt J, Looney R J. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rutuximab in the treatment of systemic lupus erythematosus.  Arthritis Rheum. 2003;  48 455-459
    CrossrefPubMedSuche in Google Scholar
  • 37 Boumpas D T, Furie R, Manzi S, Illei G G, Wallace D J, Balow J E, Vaishnaw A. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.  Arthritis Rheum. 2003;  48 719-727
    CrossrefPubMedSuche in Google Scholar
  • 38 Kalunian K C, Davis J C , Merrill J T, Totoritis M C, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.  Arthritis Rheum. 2002;  46 3251-3258
    CrossrefPubMedSuche in Google Scholar
  • 39 Schulman E S. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders.  Am J Respir Crit Care Med. 2001;  164 6-11
    PubMedSuche in Google Scholar
  • 40 Fahy J V, Fleming H E, Wong H H, Liu J T, Su J Q, Reimann J, Fick R B , Boushey H A. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects.  Am J Respir Crit Care Med. 1997;  155 1828-1834
    CrossrefPubMedSuche in Google Scholar
  • 41 Milgrom H, Fick R B , Su J Q, Reimann J D, Bush R K, Watrous M L, Metzger W J. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.  N Engl J Med. 1999;  341 1966-1973
    CrossrefPubMedSuche in Google Scholar
  • 42 Busse W, Corren J, Lanier B Q, McAlary M, Fowler-Taylor A, Cioppa G D, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.  J Allergy Clin Immunol. 2001;  108 184-190
    CrossrefPubMedSuche in Google Scholar
  • 43 Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor A F, Rohane P. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).  Pediatrics. 2001;  108 E36
    CrossrefPubMedSuche in Google Scholar
  • 44 Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F, Fowler-Taylor A, Liu J, Gupta N. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma.  J Allergy Clin Immunol. 2003;  111 278-284
    CrossrefPubMedSuche in Google Scholar
  • 45 Casale T B, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, McAlary M, Fowler-Taylor A, Racine A, Gupta N, Fick R, Della Cioppa G. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.  JAMA. 2001;  286 2956-2967
    CrossrefPubMedSuche in Google Scholar
  • 46 Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann K C, Rolinck-Werninghaus C, Grave M, Hultsch T, Wahn U. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.  J Allergy Clin Immunol. 2002;  109 274-280
    CrossrefPubMedSuche in Google Scholar
  • 47 Kopp M V, Brauburger J, Riedinger F, Beischer D, Ihorst G, Kamin W, Zielen S, Bez C, Friedrichs F, Von Berg A, Gerhold K, Hamelmann E, Hultsch T, Kuehr J. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.  J Allergy Clin Immunol. 2002;  110 728-735
    CrossrefPubMedSuche in Google Scholar
  • 48 Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E, Gustafsson H, Sandstrom T, Rak S. The effect of omalizumab on nasal allergic inflammation.  J Allergy Clin Immunol. 2002;  110 68-71
    CrossrefPubMedSuche in Google Scholar

Dr. PD K. Steinbrink

Hautklinik der Universität Mainz

Langenbeckstraße 1 · 55131 Mainz ·

eMail: steinbrink@hautklinik.klinik.uni-mainz.de